While none of the samples in our current series included EZH2 mutations, these patients might also benefit from EZH2 inhibition based on a recent study that describes that cell death pathways are upregulated in AML patient cells with mutant EZH2 [30]. Here, EZH2 is linked to acute myeloid leukemia.